2. Signaling Pathways
  3. Membrane Transporter/Ion Channel
  4. Sodium Channel
  5. Sodium Channel Isoform

Sodium Channel

 

Sodium Channel Related Products (438):

Cat. No. Product Name Effect Purity
  • HY-B0285A
    Amiloride hydrochloride
    		Inhibitor 99.83%
    Amiloride hydrochloride (MK-870 hydrochloride) is an inhibitor of both epithelial sodium channel (ENaC) and urokinase-type plasminogen activator receptor (uTPA). Amiloride hydrochloride is a blocker of polycystin-2 (PC2; TRPP2) channel.
  • HY-B0285
    Amiloride
    		Inhibitor 99.96%
    Amiloride (MK-870) is an inhibitor of both epithelial sodium channel (ENaC) and urokinase-type plasminogen activator receptor (uTPA). Amiloride is a blocker of polycystin-2 (PC2; TRPP2) channel.
  • HY-B0246
    Carbamazepine
    		Inhibitor 99.95%
    Carbamazepine is an orally active pressure-sensitive sodium ion channel blocker with an IC50 of 131 μM. Carbamazepine blocks voltage gated Na+, Ca2+, and K+ channels, and is also a HDAC inhibitor (IC50: 2 μM). Carbamazepine is an anticonvulsant and can be used for research of epilepsy and neuropathic pain.
  • HY-B0211
    Riluzole
    		Inhibitor 99.80%
    Riluzole is an anticonvulsant agent and belongs to the family of use-dependent Na+ channel blocker which can also inhibit GABA uptake with an IC50 of 43 μM.
  • HY-131615
    TPC2-A1-P
    		Agonist 99.76%
    TPC2-A1-P is a powerful and membrane permeable agonist of two pore channel 2 (TPC2) with an EC50 of 10.5 μM. TPC2-A1-P plays its role by mimicking the physiological actions of PI(3,5)P2. TPC2-A1-P also shows higher potency to induce Na2+ mobilisation from TPC2 than TPC-A1-N (HY-131614). TPC2-A1-P can be used to probe different functions of TPC2 channels in intact cells.
  • HY-A0079
    Tetracaine
    		Inhibitor 99.87%
    Tetracaine is a long-acting amino-ester used to prevent pain and induce anesthesia for the eyes; works by interfering with entry of sodium ions into nerve cells.
  • HY-Y0258A
    Benzocaine hydrochloride
    		99.31%
    Benzocaine (hydrochloride) is an orally active local agent that can suppress or relieve pain, that acts on voltage-gated Na+ channels at a common receptor, with an IC50 value of 0.8 mM at +30 mV. Additionally, Benzocaine (hydrochloride) non-competitively inhibits Ca-ATPase binding with Ca2+, with an IC50 of 47.1 mM. Benzocaine (hydrochloride) can be used in research within the field of neuromuscular regulation.
  • HY-N0239
    Bulleyaconitine A
    		Inhibitor
    Bulleyaconitine A is an analgesic and antiinflammatory drug isolated from Aconitum plants; has several potential targets, including voltage-gated Na+ channels.
  • HY-B0495
    Lamotrigine
    		Inhibitor 99.95%
    Lamotrigine (BW430C) is a potent and orally active anticonvulsant or antiepileptic agent. Lamotrigine selectively blocks voltage-gated Na+ channels, stabilizing presynaptic neuronal membranes and inhibiting glutamate release. Lamotrigine can be used for the research of epilepsy, focal seizure, et al.
  • HY-148800
    Suzetrigine
    		Inhibitor 99.91%
    Suzetrigine (VX-548) is an orally active and highly selective NaV1.8 inhibitor that acts as an analgesic. Suzetrigine is also a blocker of sodium channel protein type 10 subunit alpha. Suzetrigine is promising for research of acute pain after abdominoplasty and bunionectomy.
  • HY-108505
    QX-314 chloride
    		Inhibitor 99.83%
    QX-314 chloride is a membrane-impermeable permanently charged sodium channel blocker.
  • HY-A0081
    Fluphenazine dihydrochloride
    		Inhibitor 99.89%
    Fluphenazine dihydrochloride is a potent, orally active phenothiazine-based dopamine receptor antagonist. Fluphenazine dihydrochloride blocks neuronal voltage-gated sodium channels. Fluphenazine dihydrochloride acts primarily through antagonism of postsynaptic dopamine-2 receptors in mesolimbic, nigrostriatal, and tuberoinfundibular neural pathways. Fluphenazine dihydrochloride can antagonize Methylphenidate-induced stereotyped gnawing and inhibit climbing behaviour in mice. Fluphenazine dihydrochloride can be used for researching psychosis and painful peripheral neuropathy associated with diabetes and has potential to inhibit SARS-CoV-2.
  • HY-B0280
    Ranolazine
    		Inhibitor 99.79%
    Ranolazine (CVT 303) is an anti-angina drug that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP). Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor. Antianginal agent.
  • HY-B0448
    Phenytoin
    		Inhibitor 99.91%
    Phenytoin (5,5-Diphenylhydantoin) is a potent Voltage-gated Na+ channels (VGSCs) blocker. Phenytoin has antiepileptic activity and reduces breast tumour growth and metastasis in mice.
  • HY-B0575
    Triamterene
    		Inhibitor 99.88%
    Triamterene blocks epithelial Na+ channel (ENaC) in a voltage-dependent manner, which used as a mild diuretic. Triamterene is an inhibitor of the TGR5 receptor.
  • HY-B1546A
    Benzamil hydrochloride
    		Inhibitor 99.80%
    Benzamil hydrochloride (Benzylamiloride hydrochloride), an Amiloride analogue, is a Na+/Ca2+ exchanger (NCX) inhibitor (IC50~100 nM). Benzamil hydrochloride also is a non-selective Deg/epithelial sodium channels (ENaC) blocker, and can potentiate myogenic vasoconstriction. Benzamil hydrochloride inhibits TRPP3-mediated Ca2+-activated currents, with an IC50 of 1.1 μM.
  • HY-A0093
    Mexiletine hydrochloride
    		Inhibitor 99.92%
    Mexiletine is an orally effective antiarrhythmic agent which has also been found to be effective for myotonia and neuropathic pain. Mexiletine exerts its efficacy through blocking sodium channels (IC50 : 75±8 μM for tonic block, 23.6±2.8 μM for use-dependent block), therefore can be used for cardiovascular and neurological research.
  • HY-B0211A
    Riluzole hydrochloride
    		Inhibitor 99.88%
    Riluzole hydrochloride is an anticonvulsant agent and belongs to the family of use-dependent Na+ channel blocker which can also inhibit GABA uptake with an IC50 of 43 μM.
  • HY-B0563
    Ropivacaine
    		Inhibitor 99.93%
    Ropivacain is a potent sodium channel blocker. Ropivacain blocks impulse conduction via reversible inhibition of sodium ion influx in nerve fibrese. Ropivacaine is also an inhibitor of K2P (two-pore domain potassium channel) TREK-1 with an IC50 of 402.7 μM in COS-7 cell's membrane. Ropivacaine is used for the research of neuropathic pain management.
  • HY-147423
    Zandatrigine
    		Inhibitor 99.29%
    Zandatrigine (NBI-921352) is a sodium channel protein type 8 subunit alpha (Scn8α) blocker.